We are open as normal during COVID-19 pandemic. Order online, same day shipping out.

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561640

CAS#: 51-77-4

Description: Gefarnate is an antiulcer agent that stimulates in-vitro secretion of mucin-like glycoprotein in conjunctival tissue. It also ameliorates corneal epithelial damage in animal dry-eye models.

Price and Availability

Size Price Shipping out time Quantity
250mg USD 450 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2020-07-07. Prices are subject to change without notice.

Gefarnate, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 561640
Name: Gefarnate
CAS#: 51-77-4
Chemical Formula: C27H44O2
Exact Mass: 400.3341
Molecular Weight: 400.64
Elemental Analysis: C, 80.94; H, 11.07; O, 7.99

Synonym: Gefarnate; Geranyl farnesylacetate; Gefarnil;

IUPAC/Chemical Name: [(2E)-3,7-Dimethylocta-2,6-dienyl] (4E,8E)-5,9,13-trimethyltetradeca-4,8,12-trienoate


InChi Code: InChI=1S/C27H44O2/c1-22(2)12-8-14-24(5)16-10-17-25(6)18-11-19-27(28)29-21-20-26(7)15-9-13-23(3)4/h12-13,16,18,20H,8-11,14-15,17,19,21H2,1-7H3/b24-16+,25-18+,26-20+


Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:


1: Akagi M, Amagase K, Murakami T, Takeuchi K. Irsogladine: overview of the mechanisms of mucosal protective and healing- promoting actions in the gastrointestinal tract. Curr Pharm Des. 2013;19(1):106-14. Review. PubMed PMID: 22950502.

2: Peral A, Domínguez-Godínez CO, Carracedo G, Pintor J. Therapeutic targets in dry eye syndrome. Drug News Perspect. 2008 Apr;21(3):166-76. Review. PubMed PMID: 18560615.

3: Carmine AA, Brogden RN. Pirenzepine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in peptic ulcer disease and other allied diseases. Drugs. 1985 Aug;30(2):85-126. Review. PubMed PMID: 3928324.

4: Lux G, Rösch W. [Conservative treatment of gastric ulcer]. Med Klin. 1980 Aug 29;75(18):638-44. Review. German. PubMed PMID: 6106882.

5: Guslandi M. Review: effect of anti-ulcer drugs on gastric mucous barrier and possible cyclic AMP involvement. Int J Clin Pharmacol Ther Toxicol. 1980 Mar;18(3):140-3. Review. PubMed PMID: 6247291.

6: Vezzadini P, Ferri GL. [Medical therapy of gastric ulcer]. Clin Ter. 1979 May 15;89(3):309-17. Review. Italian. PubMed PMID: 380884.